Plus Therapeutics, Inc. has announced the initiation of the ReSPECT-LM dose optimization trial for its product REYOBIQ™ (rhenium Re186 obisbemeda) aimed at treating leptomeningeal metastases (LM).

Plus Therapeutics, Inc. has begun treating patients in its ReSPECT-LM dose optimization trial for REYOBIQ (rhenium Re186 obisbemeda), targeting leptomeningeal metastases (LM), a severe complication of ...

Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network The current dose-finding methodology ...

Add Yahoo as a preferred source to see more of our stories on Google. Sponsors should ensure dose optimisation is a part of early trial planning for oncology trials as the US Food and Drug ...

Summary of US Food and Drug Administration Chimeric Antigen Receptor (CAR) T-Cell Biologics License Application Approvals From a Statistical Perspective This review highlights strategies to integrate ...

BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (BIXT) today announced positive dose optimization results for its lead antiviral candidate, ProLectin-M, and provided an update on the ...

BOSTON, MASSACHUSETTS, May 12, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing novel antiviral therapies, today announced the ...

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs) ...

US regulators are planning to hold a meeting on emerging modeling methods that could be used to fine-tune dose selection studies and decision-making. Dose optimization is one of the most crucial parts ...

The medical community today faces a deceptively simple question: How quickly should we act when a child’s life is on the line? I’m a pediatric oncologist, so my answer won’t surprise you — I think we ...